- Home
- VCYT vs RCUS Comparison
VCYT vs RCUS Comparison
Compare VCYT & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCYT | RCUS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.6B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VCYT | RCUS |
|---|---|---|
| Price | $55.50 | $28.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $44.00 | $31.90 |
| AVG Volume (30 Days) | 1.0M | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 164.52 | N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | N/A | ★ $247,000,000.00 |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $12.35 | $45.62 |
| P/E Ratio | $159.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.92 | $8.84 |
| 52 Week High | $60.91 | $31.74 |
Technical Indicators
Market Signals| Indicator | VCYT | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 50.11 |
| Support Level | $54.25 | $19.78 |
| Resistance Level | $60.86 | $28.72 |
| Average True Range (ATR) | 2.58 | 1.39 |
| MACD | -0.69 | -0.20 |
| Stochastic Oscillator | 28.39 | 46.21 |
Price Performance
Historical ComparisonAbout VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.